Project Grant R01HL167926
Award Date
12/20/24
Completion Date
11/30/29
Dollars Obligated
$658K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chamblee, GA 30341, USA
Similar Awards
This $3,685,958 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research to develop a novel orally bioavailable drug for lowering cholesterol levels. The grant aims to complete key IND-enabling studies, including toxicology testing in dogs, safety pharmacology, and FDA regulatory support, to enable initiation of a Phase I clinical trial for the candidate PCSK9/LDLR antagonist compound "P-21"....
This $1,092,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the Medical College of Wisconsin, Inc. (MCW) to elucidate the molecular and physiological mechanisms controlling vascular function, arterial stiffness, and blood pressure regulation at the intersection of the renin-angiotensin system and the PPARG-RHOBTB1-CULLIN-3 pathways. The 7-year research program aims to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year Project Grant totaling $717,236 to the University of Iowa on December 15, 2024 under the Cardiovascular Diseases Research program (CFDA 93.837). The goal of this research is to study the role of neuronal primary cilia in hypertension, autonomic dysfunction, and body fluid imbalance. The project aims to evaluate how conditional ablation of cilia in the supraoptic nucleus affects blood pressure, drinking, urine volume, sodium...
The federal Project Grant award R01HL177553 for $787,267, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine whether genetic deletion or pharmacological inhibition of the DHCR24 enzyme in macrophages and hepatocytes can increase desmosterol levels and reduce vascular inflammation, thereby attenuating the progression of atherosclerosis. The research will leverage novel animal models and...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded Arizona State University a $407,975 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a lesion-targeted nanotherapeutic for treating vascular smooth muscle cell (VSMC) dysfunction and neointimal hyperplasia (NIH). The research project aims to integrate in vitro transcribed CARMN RNA, a long non-coding RNA critical for VSMC differentiation, into...
This $136,350 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of arterial baroreceptors in the development of hypertension. The research aims to leverage novel approaches to selectively target and interrogate sensory neurons innervating the aortic arch in mice in order to understand how chronic elevations in blood pressure may disrupt the expression of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of progranulin, an anti-inflammatory protein, in regulating endothelial function and blood pressure control. The $1,568,003 award, made on September 3, 2024, aims to determine if reduced endothelial progranulin levels contribute to the development and progression of hypertension through oxidative stress, AMPK oxidation, and...
This $114,375 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to improve the ability to identify cardiovascular disease (CVD) patients treated with statins or antiplatelet therapy at increased risk for adverse drug responses and adverse outcomes. The project will utilize data from the All of Us Research Program to: Evaluate statin prescribing patterns, adverse drug responses, and adverse outcomes...
This Project Grant award, valued at $641,960 and awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research to investigate the mechanisms by which HIV-associated proteins contribute to the development of hypertension and cardiovascular disease in people with HIV. The Augusta University Research Institute, Inc., doing business as Georgia Health Sciences, will conduct this research over a 4-year...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,129.23 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University in St. Louis. The grant supports a late-stage implementation research strategy to evaluate the effectiveness of a heart failure (HF) polypill treatment approach in India compared to usual care. The polypill combines guideline-directed medical therapies including a beta-blocker, angiotensin receptor blocker, and...